Nkarta (NKTX) Financials

Nkarta’s latest quarter shows a company still in a heavy cash-burn stage, but with a very large liquidity cushion. In Q1 2026, Nkarta reported no revenue and a net loss of $27.8 million, slightly better than the $27.4 million loss in Q4 2025 and meaningfully improved from the $31.9 million loss in Q1 2025. The company ended the quarter with $230.4 million in cash, short-term investments, and long-term investments, which gives it time to keep funding development efforts.

Operating performance remains the key issue. Nkarta generated an operating loss of $30.9 million in Q1 2026, driven by $24.99 million of R&D spending and $5.89 million of SG&A expense. While expenses were roughly in line with recent quarters, the company is still far from profitability and remains dependent on its cash reserves and investment income.

There are a few encouraging trends in the balance sheet and cash flow. Total liabilities were $86.2 million at the end of Q1 2026, down modestly from $89.3 million in Q3 2025, while equity stood at $285.9 million. The company also continues to earn meaningful interest and investment income, which helps offset a portion of operating losses.

• Nkarta ended Q1 2026 with $230.4 million in cash and investments, providing a substantial liquidity buffer.
• Interest and investment income of $2.84 million helped reduce the quarterly loss.
• Operating expenses were lower than some prior periods, with SG&A down to $5.89 million from $7.09 million in Q3 2025.
• The quarterly net loss improved versus Q1 2025, falling to $27.8 million from $31.9 million.
• Share count remained relatively stable compared with prior quarters, limiting dilution pressure in the near term.
• Nkarta still reported no revenue, so the investment case remains entirely dependent on clinical and pipeline execution.
• Cash from investing activities was positive in Q1 2026 because sales/maturities of investments exceeded purchases, but that is more a treasury-management item than a business catalyst.
• The company’s balance sheet remains asset-heavy due to marketable securities, with short-term investments of $203.1 million and long-term investments of $33.6 million.
• Nkarta posted a $28.2 million cash outflow from operations in Q1 2026, underscoring continued burn.
• R&D spending of $24.99 million remains very high relative to the company’s lack of revenue.

Longer-term, the trend is mixed. Over the last four years shown in the data, Nkarta has consistently operated at a loss and burned cash, but it also rebuilt and preserved a sizable liquidity position through prior financing and investment activity. That means the near-term story is less about earnings and more about whether the company can advance its pipeline efficiently enough to justify its cash consumption.

Bottom line: Nkarta’s financial position is still strong enough to support ongoing operations, but the business remains pre-revenue and loss-making. For retail investors, the key question is whether the company can convert its cash runway into meaningful clinical progress before the balance sheet starts to shrink too quickly.